Sherwin-Williams heads into its July 21 earnings report with options traders more cautious than they've been all year, even as analysts lift targets and short sellers quietly retreat.
The clearest tension this week is in options. Defensive positioning has jumped well above normal levels — the put/call ratio hit 0.99 on Tuesday, more than two standard deviations above its 20-day average of 0.78. That's the most defensive reading in months, sitting near the upper end of the 52-week range. The move comes after the stock slipped 2% on the day to $342.26, and is flat on the week, leaving it roughly 12% higher than a month ago. That one-month gain appears to be exactly what options traders are now hedging: a sharp re-rating that leaves little cushion heading into a print where the recent history is uncomfortable.
Short interest, by contrast, is not the story here. Bears have been covering, not adding. The float short has dropped 11.5% on the week to 3.5% — a modest level for a mega-cap specialty chemicals name. The 30-day picture is noisier: short shares rose nearly 58% through late June before reversing hard. That mid-June spike and subsequent unwind likely reflects index rebalancing or tactical positioning around the prior quarter rather than a structural bear thesis. Borrow conditions are extremely loose — availability is essentially unconstrained, with over 243 million shares available to lend — and cost to borrow runs below 0.30%, near its lowest level of the past month. There is no squeeze pressure whatsoever. The ORTEX short score sits at 37, drifting lower all week, consistent with a stock where short sellers are stepping back rather than pressing.
The analyst community, meanwhile, is tilting constructively into the print. RBC Capital raised its target to $405 on July 8, maintaining Outperform. BMO Capital moved to $400 from $355 just two days earlier, also keeping Outperform. Citigroup had already lifted its target to $380 in late June. The consensus mean target of $378.90 implies roughly 10.7% upside from current levels. The bulls' case centres on gross margin expansion — 49.4% last quarter, up 60 basis points year-on-year — and $80 million in restructuring savings kicking in. The forward EPS growth factor scores in the 92nd percentile across the universe, the standout metric in the factor profile. The bears, though, point to a housing market still constrained by affordability pressures, a 2025 sales outlook revised down to flat-to-low-single-digit growth, and a valuation that demands execution: the P/E sits near 26.8x with EV/EBITDA at 19.2x, both up meaningfully over the past month as the stock has re-rated. The P/E has expanded 1.7 turns in 30 days. The UBS downgrade to Neutral in early June — with a $330 target, now well below the stock — captures the bear case neatly: the stock is priced for a recovery that hasn't fully arrived yet.
Among close peers, the week's moves are mixed. PPG fell 3.1% on Tuesday and is down 0.6% on the week. RPM lost 1.9% Tuesday, off 2.1% weekly. AVNT bucked the trend, up 3.4% weekly, while IFF added 7.0%. The sector backdrop is not uniformly weak, which makes SHW's flat week and the jump in put buying more specific to the name than a broad chemicals selloff.
The April earnings print is the relevant data point for context. The stock fell 5.4% on the day and was down 7% over five sessions after Q1 results. That reaction — on what was a quarter where guidance was trimmed — is precisely what the put buyers appear to be pricing in again. With the next report just 13 days out, the key question is whether the second-half gross margin recovery management flagged in April is tracking ahead of, in line with, or behind that cautious guidance.
See the live data behind this article on ORTEX.
Open SHW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
